Deepak Kilari
Medical College of Wisconsin · The Medical College of Wisconsin
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Deepak Kilari as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:55 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07226713 · Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling InhibitorsMedical College of Wisconsin · recruiting · Prostate Cancer · principal investigator
- Ph2NCT07218666 · Zanzalintinib in Men With Aggressive Variant Prostate CancerDeepak Kilari · recruiting · Aggressive Variant Prostate Carcinoma · principal investigator
- Ph2NCT04635059 · Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate CancerMedical College of Wisconsin · terminated · Prostate Cancer · principal investigator
- Ph2NCT04289779 · Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr CancerDeepak Kilari · active not recruiting · Bladder Cancer · principal investigator
- N/ANCT02366494 · Micro RNAs to Predict Response to Androgen Deprivation TherapyMedical College of Wisconsin · completed · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:55 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023.J Immunother Cancer · 202326 citationsRCR 1.9
- Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.Prostate Cancer Prostatic Dis · 202518 citationsRCR 3.2
- 15 citationsRCR 0.7
- Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.Nat Med · 20267 citationsRCR 3.5
- 6 citationsRCR 0.4